Workers Compensation
The NSW Government has announced plans to set a 50 ng/mL THC limit for medicinal cannabis patients on unrestricted licences. The reform is not yet law. Injury managers need to understand what is proposed, what is still in force today, and what to document on the file in the meantime.
What the NSW medicinal cannabis driving reforms would actually change
Under the current law, any trace of THC in a NSW driver's saliva is an offence, with no exemption for prescribed medicinal cannabis patients. The announced reform would carve out a defined exemption for patients with a current medicinal cannabis prescription who hold an unrestricted licence. Those patients would be able to return a laboratory result of up to 50 ng/mL of THC in saliva without facing a drug-driving charge.
The proposed change would not legalise driving while impaired. It would establish a legal threshold for prescribed users, the same way blood alcohol concentration limits work for licensed drivers. The Minister for Roads has indicated the testing regime would generally pick up THC only in the few hours after a dose, so a patient who took their medication the night before would not be expected to be caught on the new regime. None of this is in force yet.
The proposed 50 ng/mL threshold and the two-strike warning system
Three points are proposed under the announced framework. None of them are in force until the legislation passes and commences:
- A roadside swab would still be a swab. A positive result would trigger an immediate 24-hour driving ban regardless of what the lab confirmed later.
- Patients would be required to register their prescription with Transport for NSW and complete a road safety course covering how cannabis affects driving.
- A laboratory result above 50 ng/mL would give the patient two warnings before charges followed. Warnings would reset every two years. A third positive within the window would attract the usual penalty: a fine and a minimum three-month licence suspension.
The reform, if enacted, would apply only to unrestricted licence holders. Learner, provisional, and probationary drivers would continue to face the existing zero-tolerance rule. Workers involved in a serious crash would still be tested through blood and urine, not saliva, and the proposed threshold would not protect them in that pathway.
Why this matters for return to work, even before the reform commences
On most NSW workers compensation files, the worker needs to drive at some point in their recovery: to medical appointments, to physiotherapy, to suitable duties, or to a graduated return to their pre-injury role. Under the current law, a medicinal cannabis prescription effectively forces a choice between treatment and the licence. That has created three predictable problems on NSW files today.
Workers stop or skip doses to drive, which compromises the very symptom relief the prescription was written for. Some swap to alternatives that carry higher interaction risk on a polypharmacy file. Others quietly drop the prescription off their disclosure to the insurer, which leaves injury managers blind to a medication that matters for capacity assessment.
The announced reform would remove the binary if and when it commences. It would not, however, remove the injury manager's job of confirming the worker is fit to drive on a given day or for a given task. That assessment still belongs to the treating GP, supported by an independent medication review where the picture is complex. Until the legislation passes and commences, the current zero-tolerance rule continues to apply to every NSW driver.
Medicinal cannabis on workers compensation files
Prescribed cannabis appears most often on files involving chronic pain, sleep, anxiety, and PTSD, including ex-service workers. The pattern that creates risk for injury managers is not the cannabis on its own. It is the combination.
| Combination on file | Why it matters |
|---|---|
| Medicinal cannabis + opioid | Additive sedation and respiratory depression risk. Driving capacity must be assessed against the cumulative picture, not each drug in isolation. |
| Medicinal cannabis + benzodiazepine | Significant additive sedation and impaired psychomotor performance. Highest-risk combination for safety-sensitive return-to-work duties. |
| Medicinal cannabis + pregabalin or gabapentin | Additive central nervous system depression. Common on chronic pain claims and easily missed at intake. |
| Medicinal cannabis + antidepressant | Generally low interaction risk, but worth documenting because it signals the worker is managing both pain and mood, which affects RTW plan design. |
When to request an independent medication review
The threshold for an independent review on a medicinal cannabis file is the same threshold that applies to any centrally acting medication. Three or more centrally acting medications on the script is the practical trigger. Add the worker's role: a forklift operator, driver, or scaffolder on the script warrants earlier intervention than a desk-based worker.
What injury managers should document now
Three things to capture on the file today, regardless of when the reforms commence:
- Whether the worker holds a current medicinal cannabis prescription, including product, dose, and prescriber.
- Whether the worker's role involves driving or other safety-sensitive tasks, and whether the current return-to-work plan accounts for the medication timing under the current zero-tolerance law.
- Once the reform commences, whether the worker has registered the prescription with Transport for NSW and completed the road safety course.
Document this once. Revisit it at every certificate review. The proposed reform would change what is legal at the roadside if and when it passes. It does not change the injury manager's duty to align medication, capacity, and the return-to-work plan today.
Key Takeaways
- The reforms have been announced by the NSW Government but are not yet law. Current zero-tolerance rules still apply to every NSW driver, including prescribed medicinal cannabis patients.
- The proposed framework would set a 50 ng/mL THC saliva threshold for prescribed patients on unrestricted licences.
- A positive roadside swab would still trigger an immediate 24-hour driving ban, regardless of the later lab result.
- Patients would need to register their prescription with Transport for NSW and complete a road safety course before the exemption applied.
- The proposed system would be reviewed after one year once it commenced.
- The interaction risk on workers compensation files comes from cannabis sitting alongside opioids, benzodiazepines, or pregabalin, not the cannabis alone, and that risk picture applies regardless of the reforms.
Frequently Asked Questions
Are these NSW medicinal cannabis driving reforms in effect right now?
No. As at 04/06/2026 the reforms have been announced by the NSW Government but have not yet been legislated or commenced. The current zero-tolerance rule still applies to every NSW driver, including prescribed medicinal cannabis patients. The proposed system is also slated for review one year after it does take effect.
Would the proposed THC limit apply to workers on a return-to-work plan?
Only once the reform commences, and only if the worker holds an unrestricted licence and has registered their prescription with Transport for NSW. Workers on a learner, provisional, or probationary licence would not be covered, and any trace of THC would remain an offence for them.
Should injury managers ask about medicinal cannabis at claim intake today?
Yes. A prescription for medicinal cannabis affects driving capacity under the current law, return-to-work plan design, and the interaction risk picture if opioids or benzodiazepines are also on the file. Capture it the same way you capture any other prescribed medication.
When should an independent medication review be triggered?
When medicinal cannabis sits alongside opioids, benzodiazepines, pregabalin, or other centrally acting medications, or when the worker has a safety-sensitive role. The review documents the interaction risk and gives the treating GP specific recommendations.
Primary source: NSW Government and Transport for NSW announcement on medicinal cannabis driving reforms, 2026, following the 2024 NSW Drug Summit recommendations.
